Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease

Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease

Over 4% of the global population is estimated to live with autoimmune disease, necessitating immunosuppressive treatment that is often chronic, not curative, and carries associated risks. B cells have emerged as key players in disease pathogenesis, as evidenced by partial responsiveness to B cell de...

Full description

Bibliographic Details
Main Authors: Binghao J. Peng, Andrea Alvarado, Hangameh Cassim, Soprina Guarneri, Steven Wong, Jonathan Willis, Julia SantaMaria, Ashley Martynchuk, Victoria Stratton, Darshil Patel, Chien-Chung Chen, Yan Li, Gwendolyn K. Binder, Rebecca Dryer-Minnerly, Jinmin Lee, Samik Basu
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
chimeric antigen receptor T cell
CAR T cell
autoimmune disease
preclinical study
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050124000834

Internet

http://www.sciencedirect.com/science/article/pii/S2329050124000834

Similar Items